MW
MARY WALSH
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC · Washington, DC · registered since 2024
Registered · LDAActive
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
5 agencies contacted
Activity
filings by quarter
Works on
Background
Career
BI
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Washington, DC
2024 - present
Specific issues
Issues related to Animal Health Issues related to One Health Issues Related to Compounding Animal Drugs from Bulk Substances Farm, Food and National Security Act of 2024 (H.R. 8467) Foreign Animal Disease Prevention Surveillance and Rapid Response Act of 2023 (H.R. 3419/S.1666)
Issues related to FY2024 Appropriations
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act (H.R. 4818/S.2407) The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to Animal Health Issues related to One Health Issues Related to Compounding Animal Drugs from Bulk Substances Animal Drug User Fee Amendment of 2023 (H.R. 1418/S.1844) Foreign Animal Disease Prevention Surveillance and Rapid Response Act of 2023 (H.R. 3419/S.1666)